Vancomycin-resistant enterococci

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 819-829

  Palmer, Shirley M ^a   Rybak, Michael J ^b,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CLINAFLOXACIN; GENTAMICIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; DRUG USE; ENTEROCOCCUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; UNITED STATES; VANCOMYCIN;

EID: 0029742420     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
2. Moellering RC Jr. Emergence of enterococcus as a significant pathogen. Clin Infect Dis 1992;14:1173-8.
3. Lewis CM, Zervos MJ. Clinical manifestations of enterococcal infection. Eur J Clin Microbiol Infect Dis 1990;9:111-17.
4. Gordon S, Swenson JM, Hill BC, et al. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. J Clin Microbiol 1992;30:2373-8.
5. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections. Medicine 1995;74:191-200.
6. Ruoff KL, de la Maza L, Murtagh MJ, Spargo JD, Ferraro MJ. Species identities of enterococci isolated from clinical specimens. J Clin Microbiol 1990;28:435-7.
7. Bush LM, Calmon J, Cherney CL, et al. High-level penicillin resistance among isolates of enterococci: implications for treatment of enterococcal infections. Ann Intern Med 1989;110:515-20.
8. Nachamkin I, Axelrod P, Talbot GH, et al. Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol 1988;26:1287-91.
9. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65.
10. Murray BE, Mederski-Samaroj B. Transferable β-lactamase: a new mechanism for in vitro resistance in Streptococcus faecalis. J Clin Invest 1983;72:1168-71.
11. Moellering RC, Korzeniowski OM, Sande M, Wennersten CB. Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis 1979;140:203-8.
12. Leclercq R, Deroit E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
13. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
14. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR 1993;42:597-9.
15. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Ann Intern Med 1995;123:250-9.
16. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-53.
17. Quintiliani R Jr, Evers S, Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 1993;167:1220-3.
18. Williamson RC, Al-Obeid S, Shlaes JH, Goldstein FW, Schlaes DM. Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis 1989;159:1095-1104.
19. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993;175:117-27.
20. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37:1563-71.
21. Gold HS, Unal S, Cercenado E, Thauvin-Eliopoulos C, et al. A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother 1993;37:1604-9.
22. Arthur M, Molinas C, Bugg TDH, Wright GD, Walsh CT, Courvalin P. Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992;36:867-9.
23. Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147; biosynthesis of a depsipeptide pedtidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 1991;30:10408-15.
24. Wright GD, Walsh CT. D-Alanyl-D-alanine ligases and the molecular mechanism of vancomycin resistance. Accounts Chem Res 1992;25:468-73.
25. Al-Obeid S, Billot-Klein D, Van Heijenoort J, Collatz E, Gutmann L. Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-β-lactam synergy in low-level vancomycin resistant Enterococcus faecium D366. FEMS Microbiol Lett 1992;91:79-84.
26. Shlaes DM, Al-Obeid S, Shlaes JH, Boisivon A, Williamson R. Inducible, transferable resistance to vancomycin in Enterococcus faecium D399. J Antimicrob Chemother 1989; 23:503-8.
27. Shlaes DM, Etter L, Gutmann L. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother 1991;35:776-9.
28. Leclercq R, Bingen E, Su QH, Lamber-Zechovski N, Courvalin P, Duval J. Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991;35:92-8.
29. Gutmann L, Al-Obeid S, Billot-Klein D, Guerrier ML, Collatz E. Synergy and resistance to synergy between β-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium. Antimicrob Agents Chemother 1994;38:824-9.
30. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992;36:2201-3.
31. Handwerger S, Perlman DC, Altarac D, McAuliffe V. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992;14:655-61.
32. Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
33. Frieden TR, Munsiff SS, Low DE, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-9.
34. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-5.
35. Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
36. Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.
37. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-5.
38. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33.
39. Sastry V, Brennan PJ, Levy MM, et al. Vancomycin-resistant enterococci: an emerging pathogen in immunosuppressed transplant recipients. Transplant Proc 1995;27:954-5.
40. Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-16.
41. Flournoy DJ. Antimicrobial susceptibilities of bacteria from nursing home residents in Oklahoma. Gerontology 1994;40:53-6.
42. Sahm DF, Olsen L. In vitro detection of enterococcal vancomycin resistance. Antimicrob Agents Chemother 1990;34:1846-8.
43. Tenover FC, Tokars J, Swenson J, Paul S, Spitalny K, Jarvis W. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J Clin Microbiol 1993;31:1695-9.
44. Willey BM, Kreiswirth BN, Simor AE, et al. Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol 1992;30:1621-4.
45. Swenson JM, Ferraro MJ, Sahm DF, et al. New vancomycin disk diffusion breakpoints for enterococci. J Clin Microbiol 1992;30:2525-8.
46. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:247-64.
47. Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with history of penicillin allergy. Ann Allergy Asthma Immunol 1995;74:167-70.
48. Green M, Barbadora K, Michaels M. Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J Clin Microbiol 1991;29:2503-6.
49. Chow JW, Kuritza A, Schlaes DM, Green M, Sahn DF, Zervos MJ. Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol 1993;31:1609-11.
50. Norris AH, Reilly JP, Edelstein PH, Brennan PH, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44.
51. Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:1364-6.
52. Johnson CC, Taylor S, Pitsakis P, May P, Levison ME. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother 1992;36:2342-5.
53. Mobarakai N, Quale JM, Landman D. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother 1994;38:385-7.
54. Collins LA, Malonski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:598-601.
55. Cerwinka S, Bompart F, Kreter B, Savarese J. Emergency use and accelerated development of Synercid (RP59500) for treatment of vancomycin-resistant Enterococcus faecium (VREF) infections [abstr]. Presented at the meeting on Bacterial Multidrug Resistance: Overcoming the Multidrug Resistance Challenge, Bethesda, MD, January 23-24, 1995.
56. Caron F, Carbon C, Gutmann L. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1991;164:888-93.
57. Caron F, Pestel M, Kitzis MD, Lemeland JF, Humbert G, Gutmann L. Comparison of different β-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1995;171:106-12.
58. Fraimow HS, Venuti E. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1992;36:1563-6.
59. Sahm DF, Koburov GT. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother 1989;33:71-7.
60. Landman D, Mobarakai NK, Quale JM. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antmicrob Agents Chemother 1993;37:1904-8.
61. Burney S, Landman D, Quale JM. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother 1994;38:1668-70.
62. Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993;37:2069-73.
63. French P, Venuti E, Fraimow HS. In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. Antimicrob Agents Chemother 1993;37:2736-9.
64. Quale JM, Landman D, Mobarakai N. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with ciprofloxacin and novobiocin. J Antimicrob Chemother 1994;34:797-802.
65. Jones RN. Should novobiocin be clinically reevaluated? Diagn Microbiol Infect Dis 1989;12:363-5.
66. O'Donovan CA, Fan-Havard P, Tecson-Tumang FT, Smith SM, Eng RHK. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis 1994;18:105-9.
67. Graninger W, Ragette R. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992;15:49-57.
68. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995;20:296-301.
69. Sanyal D, Williams AJ, Johnson AP, George RC. The emergence of vancomycin resistance in renal dialysis. J Hosp Infect 1993;24:167-73.
70. Schwalbe RS, Stapleton JT, Billigan PH. Emergence of vancomycin resistance in coagulase negative staphylococci. N Eng J Med 1987;316:927-8.
71. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP. Vancomycin-resistance in S. haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990;28:2064-8.
72. Noble WC, Virani Z, Cree R. Cotransfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93:195-8.